Stock analysts at Zacks Research initiated coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Get Free Report) in a research report issued to clients and investors on Thursday, Zacks reports. The firm set a “hold” rating on the stock.
Other equities analysts have also recently issued reports about the company. TD Cowen started coverage on Lycia Therapeutics in a report on Tuesday. They issued a “buy” rating on the stock. Evercore initiated coverage on shares of Lycia Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $43.00 price target for the company. Jefferies Financial Group began coverage on shares of Lycia Therapeutics in a report on Tuesday. They set a “buy” rating and a $50.00 price objective on the stock. Wall Street Zen raised shares of Lycia Therapeutics to a “hold” rating in a research note on Saturday, October 31st. Finally, Guggenheim began coverage on shares of Lycia Therapeutics in a report on Tuesday. They set a “buy” rating and a $75.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $54.00.
Check Out Our Latest Stock Analysis on LYCA
Lycia Therapeutics Stock Up 4.1%
Lycia Therapeutics stock opened at $33.07 on Thursday. Lycia Therapeutics has a 12-month low of $22.19 and a 12-month high of $36.49.
Insider Buying and Selling
In related news, major shareholder Venrock Healthcare Capital Par bought 1,952,705 shares of Lycia Therapeutics stock in a transaction on Monday, October 26th. The stock was acquired at an average price of $18.04 per share, with a total value of $35,226,798.20. Following the acquisition, the insider directly owned 6,785,437 shares of the company’s stock, valued at $122,409,283.48. This represents a 40.41% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders bought 2,078,749 shares of company stock valued at $38,526,342.
Lycia Therapeutics Company Profile
Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.
Further Reading
- Five stocks we like better than Lycia Therapeutics
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
